Darunavir with cobicistat with emtricitabine and tenofovir alafenamide
Brand: Symtuza
PBAC's latest decision on Darunavir with cobicistat with emtricitabine and tenofovir alafenamide: Recommended with restriction (2019). Considered for Treatment of human immunodeficiency virus (HIV) infection in adults and adolescents ≥40 kg, for both treatment-naïve patients and treatment-experienced patients with virological or clinical failure.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Adults and adolescents ≥40 kg with HIV infection, including treatment-naïve patients and treatment-experienced patients who have experienced virological or clinical failure after at least one antiretroviral regimen
Therapy area
Infectious disease
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
Virological suppression
Pivotal trial size
1,141 patients
Key trials
EMERALD, AMBER, Mills 2015
Comparator
Prezcobix (darunavir/cobicistat) with a mixed comparator of Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide) at a relative weighting of 94:6
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated as this is a cost-minimisation comparison of equi-effective regimens